Emily S Riser MD
Neuroimaging, Neuroimmunology/Multiple Sclerosis
Medical Director/ Tanner Center for MS
Join to view full profile
3105 Independence DriveSte 101Birmingham, AL 35209
Phone+1 205-803-2210
Fax+1 205-803-2214
Dr. Riser is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Emily Riser is a neurologist based in Birmingham, AL, specializing in neuroimaging and neuroimmunology, with a focus on multiple sclerosis. She completed her medical education and residency at the University of Alabama, followed by an internship at the Medical University of South Carolina. Dr. Riser has extensive experience in general neurology, multiple sclerosis, neuromuscular medicine, and neuroimmunology, and she currently serves as the Medical Director at Alabama Neurology. Her research interests include treatments for multiple sclerosis, as demonstrated by her involvement in several clinical trials and publications in respected journals. Dr. Riser has received accolades for her contributions to the field, including CMS Meaningful Use Stage 1 Certification.
Education & Training
Alabama Neurological InstitutePost-Doctoral Fellowship, 2008 - 2009
University of Alabama Medical CenterResidency, Neurology, 1985 - 1988
Medical University of South CarolinaInternship, Internal Medicine, 1984 - 1985
University of Alabama School of MedicineClass of 1984
Vanderbilt UniversityB.S., 1980
Certifications & Licensure
AL State Medical License 1985 - 2026
SC State Medical License 1984 - 1985
American Board of Psychiatry and Neurology Neurology
American Society of NeurorehabilitationNeurorehabilitation- United Council for Neurological SubspecialtiesNeuroimaging
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MacPractice MD, MacPractice, Inc., 2012, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Clinical Trials
- A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis Start of enrollment: 2005 Oct 01
- TYSABRI Global Observational Program in Safety Start of enrollment: 2007 Jan 01
- BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) Start of enrollment: 2008 Apr 24
Publications & Presentations
PubMed
- Switching from Rituximab to Eculizumab in US Patients with Neuromyelitis Optica Spectrum Disorder: Impact on Hospitalizations.Justin Lee, Adrian Kielhorn, Sami Fam, Emily Riser, Eoin P Flanagan
Neurology and Therapy. 2025-12-01 - Open label placebo to treat fatigue in people with multiple sclerosis: feasibility and preliminary effects.Navneet Kaur Baidwan, Tracy Tracy, Chia-Ying Chiu, Tanjila Nawshin, Teri Hoenemeyer
Pilot and Feasibility Studies. 2025-07-03 - 2 citationsImmune response to influenza vaccine in patients with relapsing multiple sclerosis treated with ofatumumab: Results from an open-label, multicenter, phase 4 study.Brian Steingo, Adnan Subei, Emily Riser, Jeffrey Gitt, James Stankiewicz
Multiple Sclerosis and Related Disorders. 2025-05-01
Professional Memberships
- Member
External Links
- Tanner Center for MShttp://alaneuro.com
- National MS Societyhttp://nmss.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
